Peroxisome Proliferator-activated Receptor-γ As A Novel and PromisingTarget For Treating Cancer Via Regulation of Inflammation: A Brief Review / S. Yuvaraj, B.R. Prashantha Kumar
Abstract: Peroxisome proliferator activated receptors (PPARs) are a group of nuclear receptors andthe ligand-activated intracellular transcription factors that are known to play a key role in physiologicalprocesses such as cell metabolism, proliferation, differentiation, tissue remodeling, inflammation,and atherosclerosis. However, in the past two decades, many reports claim that PPARs also play animperious role as a tumor suppressor. PPAR- gamma (PPARγ), one of the best-known from the familyof PPARs, is known to express in colon, breast, bladder, lung, and prostate cancer cells. Its function intumour cells includes the modulation of several pathways involved in multiplication and apoptosis.The ligands of PPARγ act by PPARγ dependent as well as independent pathways and are also foundto regulate different inflammatory mediators and transcription factors in systemic inflammation and intumor microenvironment. Both synthetic and natural ligands that are known to activate PPARγ, suppressthe tumor cell growth and multiplication through the regulation of inflammatory pathways, asfound out from different functional assays and animal studies. Cancer and inflammation are interconnectedprocesses that are now being targeted to achieve tumor suppression by decreasing the risks andburden posed by cancer cells. Therefore, PPARγ can serve as a promising target for development ofclinical drug molecule attenuating the proliferation of cancer cells. In this perspective, this mini reviewhighlights the PPARγ as a potential target for drug development aiming for anti-inflammatoryand thereby suppressing tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Mini-reviews in ... medicinal chemistry - 22(2022), 1, Seite 12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuvaraj, S. [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (12 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL01118003X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL01118003X | ||
| 003 | DE-627 | ||
| 005 | 20231128075956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL01118003X | ||
| 035 | |a (KFL)prod_DARH_.DBA4AD637F19AFFA9CCFF18CC9AAD5EFA14EA3CA | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Yuvaraj, S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Peroxisome Proliferator-activated Receptor-γ As A Novel and PromisingTarget For Treating Cancer Via Regulation of Inflammation: A Brief Review |c S. Yuvaraj, B.R. Prashantha Kumar |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (12 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract: Peroxisome proliferator activated receptors (PPARs) are a group of nuclear receptors andthe ligand-activated intracellular transcription factors that are known to play a key role in physiologicalprocesses such as cell metabolism, proliferation, differentiation, tissue remodeling, inflammation,and atherosclerosis. However, in the past two decades, many reports claim that PPARs also play animperious role as a tumor suppressor. PPAR- gamma (PPARγ), one of the best-known from the familyof PPARs, is known to express in colon, breast, bladder, lung, and prostate cancer cells. Its function intumour cells includes the modulation of several pathways involved in multiplication and apoptosis.The ligands of PPARγ act by PPARγ dependent as well as independent pathways and are also foundto regulate different inflammatory mediators and transcription factors in systemic inflammation and intumor microenvironment. Both synthetic and natural ligands that are known to activate PPARγ, suppressthe tumor cell growth and multiplication through the regulation of inflammatory pathways, asfound out from different functional assays and animal studies. Cancer and inflammation are interconnectedprocesses that are now being targeted to achieve tumor suppression by decreasing the risks andburden posed by cancer cells. Therefore, PPARγ can serve as a promising target for development ofclinical drug molecule attenuating the proliferation of cancer cells. In this perspective, this mini reviewhighlights the PPARγ as a potential target for drug development aiming for anti-inflammatoryand thereby suppressing tumors | ||
| 700 | 1 | |a Kumar, B.R. Prashantha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mini-reviews in ... medicinal chemistry |d Hilversum, the Netherlands [u.a.] : Bentham Science Publ., 2001 |g 22(2022), 1, Seite 12 |h Online-Ressource |w (DE-627)KFL000006394 |w (DE-600)2104083-7 |w (DE-576)273887203 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g pages:12 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-5575&volume=22&issue=1&spage=3 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |h 12 | ||